BPC-157: 2026 Evidence Overview

What animal models show, what the two small human studies actually say, and where the limits of the current evidence lie.

What BPC-157 Is

BPC-157 is a synthetic pentadecapeptide made of 15 amino acids (CAS 137525-51-0, molecular weight 1419.5 g/mol). Its sequence is derived from a protective protein found in human gastric juice, which is also where the name Body Protection Compound comes from. In research, it is among the most frequently studied peptides in the field of tissue regeneration.

Commercially, BPC-157 is typically offered at a purity standard of at least 99 percent (HPLC). Its current research stage is classified as "early clinical studies", a stage between broad animal research and the first, still very small studies in humans. A complete research profile with all reference data is available in our compound database.

Basic research describes several cellular mechanisms for BPC-157: involvement in angiogenesis through the VEGFR2-AKT-eNOS pathway, modulation of inflammatory messengers, and support of cell migration through the FAK-paxillin pathway. How these mechanisms actually interact in the human body has not yet been conclusively established.

In our database, we place BPC-157 in the Regeneration category, alongside the related peptide TB-500. Both are discussed in similar research contexts but differ in amino acid sequence and origin.

The "early clinical studies" label is not fixed, it is a snapshot. It can change once new, methodologically stronger work is published, in either direction.

Preclinical Research: What Animal Models Show

A systematic review by Vasireddi and colleagues evaluated the literature from 1993 to 2024. Of 544 screened articles, 36 studies were included, 35 of them preclinical. The included animal studies examined fractures, tendon ruptures, ligament injuries, and muscle damage.

In these models, several studies described improved functional, structural, and biomechanical outcomes. As possible mechanisms, the authors cite increased growth hormone receptor expression, involvement in angiogenesis-related signaling pathways, and a reduction in inflammatory cytokines.

The review itself followed a structured screening process with two independent reviewers across three phases, a sign of methodological care in selecting the literature, independent of the quality of the individual included studies.

Important limitation: animal models do not translate directly to humans. The authors themselves classify the included evidence as level IV and V, meaning comparatively low evidence strength.

Put differently: for every 35 animal studies in the included literature, there is only a single clinical study in humans. That ratio illustrates how wide the gap between basic research and clinical testing still is for BPC-157.

Clinical Research: What the Few Human Studies Show

Controlled studies in humans are still lacking. What exists are two small, retrospective case series without a control group.

Within the review mentioned above, the authors identified a retrospective evaluation in which 12 people received an intra-articular knee injection. 7 of them reported pain relief lasting more than six months.

Lee and Padgett reviewed patient charts from a single practice in 2021, the Institute for Hormonal Balance in Orlando, Florida. Data was collected through chart review followed by a phone call, in which people rated their pain intensity and perceived improvement in retrospect. Standardized questionnaires on function, quality of life, or mobility were not used.

Of 17 people who had received an injection, 16 could be reached by phone. 12 had received BPC-157 alone, of whom 11 reported noticeable improvement. Overall, 14 of 16 respondents (87.5 percent) reported improvement, collected without standardized measurement tools and without a control group.

The two case series were produced independently of each other, yet they overlap both in the body region studied, the knee, and in design: retrospective, uncontrolled, and based on respondents' own self-reports.

What Is Not Established

For BPC-157, there is so far no placebo-controlled, randomized trial in humans and no study with a relevant number of participants. Both available human data sets come from retrospective chart reviews and phone surveys without a control group, without blinding, and without validated measurement instruments.

Both studies also rely on the respondents' own subjective feedback. There is no comparison with a group that did not receive BPC-157, and no blinding that would rule out a placebo effect.

BPC-157 is not approved as a medication in any of the three jurisdictions, Germany, the EU, or the United States. It has not gone through a regulatory approval process, there is no dosing recommendation, and independently replicated results across multiple research groups are still missing.

The scope of the data is narrow in content, too: both available human studies dealt exclusively with knee pain. For other commonly discussed areas, such as individual tendon injuries in recreational sports, there simply is no dedicated human study.

Observations from animal models are not proof in humans, and two small, uncontrolled case series are no substitute for a randomized, placebo-controlled trial.

Safety Data According to the Literature

According to the review by Vasireddi et al., preclinical safety studies showed no adverse effects across several organ systems. Clinical safety data in humans, however, were not found by the authors, a point they state explicitly in the paper.

Regarding metabolism, the same paper describes a half-life of less than 30 minutes, breakdown via the liver, and clearance via the kidneys. On a mechanistic level, it is discussed that the same signaling pathways driving angiogenesis and cell growth in tissue regeneration could theoretically also support existing tumor growth. A causal link in humans is therefore not established, only named as an open question.

A further risk named by the study authors themselves does not concern the molecule but its manufacturing: products from unregulated production carry a contamination risk, independent of the substance itself.

Long-term data spanning years of use do not exist, neither from controlled studies nor from systematic surveillance.

One point worth keeping in mind: "no adverse effects in animal models" does not mean "safe in humans". Safety profiles only translate across species to a limited degree, and that applies to risks just as much as to the effects observed in animal studies.

Legal Status in Germany, the EU, and the United States

BPC-157 is not approved as a medication in Germany, the rest of the EU, or the United States, and it is not classified as a food product either. Commercially, it is sold exclusively as a research chemical labeled RUO (research use only), intended for laboratory and research purposes, not for use in humans. According to the cited review, the US regulatory agency FDA has not granted approval for the substance either.

The legal status barely differs between the three regions, in all three, an approval process for human use is simply absent. Sale as a research chemical to laboratories is independent of that.

For comparison: an approved medication goes through preclinical testing, controlled clinical phases, and a regulatory benefit-risk assessment before reaching the market. That process has not taken place for BPC-157, neither in Germany, the EU, nor the United States.

What RUO means in detail, we explain in our Peptide 1x1.

WADA Prohibited List

The vendor smartpeptides.de states on its product page that BPC-157 has been on the World Anti-Doping Agency (WADA) prohibited list since 2022. The review by Vasireddi et al. also confirms that its use is banned in professional sports.

For anyone subject to an anti-doping code, this is relevant information, independent of the rest of the evidence base. The WADA code does not distinguish between a research chemical and a medication, what matters is solely the pharmacological effect of the listed substance.

How to Read Further

This summary does not replace reading the original papers yourself. All studies mentioned here, plus further compounds with their respective sources, are collected in our research hub. The complete BPC-157 research profile with reference data, mechanism, and FAQ is available in our compound database.

New studies on BPC-157 appear continuously, we update our research hub accordingly.

All substances mentioned here are intended exclusively for research purposes, this is not medical advice and not a recommendation for use in humans.

Sources

• Vasireddi et al. 2025, HSS Journal, PMID 40756949
• Lee & Padgett 2021, Alternative Therapies in Health and Medicine, PMID 34324435
• smartpeptides.de, Produktseite BPC-157 (WADA-Hinweis) · Ad

Frequently asked questions

Are there controlled human studies on BPC-157?
No. So far, there are no placebo-controlled, randomized studies in humans. What is available are two small, retrospective case series without a control group, covering fewer than 30 people in total.

Is BPC-157 approved as a medication?
No. BPC-157 is not approved as a medication in Germany, the rest of the EU, or the United States. It is sold exclusively as a research chemical for laboratory and research purposes.

Why does BPC-157 come up in connection with anti-doping rules?
Because, according to vendor statements, it has been on the World Anti-Doping Agency's (WADA) prohibited list since 2022. A systematic review published in 2025 also confirms that its use is banned in professional sports.